SLU-PP-332
$127.99
SLU-PP-332 is a synthetic small molecule pan-agonist of estrogen-related receptors (ERRα, ERRβ, ERRγ) — nuclear receptors that regulate mitochondrial biogenesis, oxidative metabolism, and energy expenditure gene networks. In research settings, SLU-PP-332 is studied for its interactions with ERR-mediated transcriptional pathways and downstream metabolic signaling.
BioRhex supplies SLU-PP-332 as a research compound manufactured in a GMP-compliant US facility, tested to ≥99% purity via HPLC and mass spectrometry, and supplied strictly for controlled laboratory research — not for human or animal use.
- In stock
- COA-verified
- ≥99% purity.
- USA manufactured.
- In stock
- COA-verified
- ≥99% purity.
- USA manufactured.
- COA-verified
- In stock
- ≥99% purity.
- USA manufactured.
What Is SLU-PP-332?
SLU-PP-332 is a synthetic small molecule pan-agonist of estrogen-related receptors (ERRα, ERRβ, ERRγ) — nuclear receptors that regulate mitochondrial biogenesis, oxidative metabolism, and energy expenditure gene networks. In research settings, SLU-PP-332 is studied for its interactions with ERR-mediated transcriptional pathways and downstream metabolic signaling.
BioRhex supplies SLU-PP-332 as a research compound manufactured in a GMP-compliant US facility, tested to ≥99% purity via HPLC and mass spectrometry, and supplied strictly for controlled laboratory research — not for human or animal use.
Compound Overview
SLU-PP-332 is a pan-ERR agonist studied for its mitochondrial and metabolic transcriptional signaling effects. In vitro and preclinical research models examine how SLU-PP-332 may influence:
• ERRα, ERRβ, and ERRγ receptor activation and transcriptional coactivation
• Mitochondrial biogenesis gene network modulation via PGC-1α pathway interactions
• Oxidative phosphorylation and fatty acid oxidation pathway signaling
• Skeletal muscle fiber metabolic remodeling in preclinical models
• Exercise-associated metabolic gene pathway activation in research systems
All findings referenced are from controlled research environments and do not represent clinical outcomes or therapeutic claims.
History of SLU-PP-332
SLU-PP-332 was developed at St. Louis University as part of a research program into synthetic ERR agonists. Estrogen-related receptors regulate overlapping but distinct gene networks related to mitochondrial function, and developing potent pan-agonist compounds required careful structure-activity optimization.
Research interest in ERR agonists grew from preclinical findings suggesting that ERR activation could replicate aspects of exercise-induced mitochondrial adaptation in skeletal muscle tissue models.
SLU-PP-332 represents one of the more potent pan-ERR agonist research compounds currently under investigation in metabolic pathway biology.
Molecular Structure
Small molecule compound — Synthetic ERRα/β/γ pan-agonist (proprietary structure)
Research Findings
Published and preclinical research on SLU-PP-332 covers several areas of scientific investigation, including:
ERR receptor activation research: Studies examine SLU-PP-332’s binding affinity and transcriptional activation potency across ERR receptor subtypes.
Mitochondrial biogenesis modeling: Research investigates PGC-1α coactivation and downstream mitochondrial gene expression changes in cellular models.
Oxidative metabolism research: Laboratory models evaluate fatty acid oxidation and oxidative phosphorylation pathway activity in response to ERR agonism.
Exercise-mimetic gene network research: Preclinical studies explore ERR agonism-associated metabolic gene expression patterns in skeletal muscle tissue models.
All findings referenced are from controlled, non-clinical research models and do not imply therapeutic or clinical application.
References
FAQ
Q: What type of research is SLU-PP-332 used for?
Q: What type of research is SLU-PP-332 used for?
A: SLU-PP-332 is used in laboratory research settings. All supplied compounds are intended strictly for in vitro and preclinical research purposes. Use is limited to controlled scientific environments.
Q: Where is BioRhex’s SLU-PP-332 manufactured?
Q: Where is BioRhex’s SLU-PP-332 manufactured?
A: All BioRhex compounds, including SLU-PP-332, are manufactured in a GMP-compliant facility located in the United States.
Q: What testing does BioRhex conduct on SLU-PP-332?
Q: What testing does BioRhex conduct on SLU-PP-332?
A: Every batch of SLU-PP-332 undergoes third-party HPLC purity testing, mass spectrometry identity verification, and sterility testing. A Certificate of Analysis is included with every order, documenting batch-specific purity data at a ≥99% threshold.
Q: Is SLU-PP-332 approved for human use?
Q: Is SLU-PP-332 approved for human use?
A: No. SLU-PP-332 is not FDA-approved and is not intended for human or animal administration. It is supplied exclusively for laboratory research purposes.
Q: Who should handle this compound?
Q: Who should handle this compound?
A: Only qualified personnel in controlled laboratory settings following appropriate safety and handling protocols.
Research Use Only
All BioRhex compounds are supplied strictly for laboratory research purposes. Not for human or animal consumption, medical use, or therapeutic application. SLU-PP-332 is not FDA-approved for any medical purpose. Nothing on this page should be interpreted as health guidance or applied outside controlled research settings.
RELATED PRODUCTS
AOD9604 (5mg)
BPC-157
BPC-157 + TB-500
CJC (no DAC) + Ipamorelin (10mg)
